A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants

Longwood Pharmaceuticals (Hangzhou) Co., Ltd.1 个研究点分布在 1 个国家目标入组 76 人开始时间: 2026年3月13日最近更新: 2026年3月20日

干预措施

试验速览

阶段: 1 期
状态: 招募中
发起方
入组人数: 76
试验地点: 1
主要终点: Number and proportion of participants with a treatment-emergent adverse event (TEAE)

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This study is a randomized, double-blind, placebo-controlled clinical trial featuring both single ascending dose (SAD), food effect and multiple ascending dose (MAD) phases intended to evaluate the safety, tolerability, PK, PD, and active metabolites of LWP779 after oral administration in healthy participants.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Parallel
主要目的: Treatment
盲法: Double (Participant, Investigator)

入排标准

年龄范围: 18 Years 至 65 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 是

入选标准

•1. Capable of understanding the written informed consent document; willingly provides valid, signed written informed consent;
•2. Males and females aged 18 to 65 years old (inclusive) at the time of signing the ICF.
•3.No history of past or current diseases or abnormalities involving the cardiac, hepatic, renal, gastrointestinal, nervous, respiratory, or ocular systems, as well as psychiatric or metabolic abnormalities, that are clinically significant as judged by the investigator.
•4.Participants must be confirmed healthy through medical history, VS, physical examination, clinical laboratory tests , and a 12-lead ECG;
•5. Body mass index (BMI) of 18.0 to 32.0 kg/m2 inclusive and body weight not less than 50 kg at the time of screening and Day -
•6. Participants must agree to take the investigator-approved effective contraceptive measures during the trial as required by the investigator.
•7.Normal renal function (defined as eGFR ≥ 80 mL/min/1.73 m2) at screening and Day -
•8. Ability to swallow and retain oral medication.
•9.No suicidal ideation, as demonstrated by a score of "0" on the Columbia Suicide Severity Rating Scale (C-SSRS) at screening or Day -1.

排除标准

•1.Known hypersensitivity to LWP779 or any of its constituents.
•2.Known or suspected tumor.
•3.History of unexplained syncope, symptomatic hypotension or hypoglycemia.
•4.Presence of orthostatic hypotension at screening or Day -
•5.Participants with any ocular diseases (e.g., glaucoma, fundus macular degeneration, corneal lesions, retinopathy, etc.).
•6.Family history of long QTc syndrome; mean QTcF interval >450 msec for males and >470 msec for females or presence of any other mean ECG abnormality at screening or Day -1 deemed clinically significant by the PI/medical delegate.
•7.Resting pulse rate <45 bpm or >100 bpm at screening, or Day -
•8.Systolic blood pressure < 90 or >160 mm Hg and/or diastolic blood pressure < 50 or > 95 mm Hg at screening or Day -
•9.History of unstable ischemic heart disease, recent (within 6 months of screening) myocardial infarction, or presence of clinically significant cardiac arrhythmia.
•10.Ongoing liver disease or unexplained liver function test (LFT) elevations, defined as ALT, AST, gamma glutamyl transferase (GGT), alkaline phosphatase (ALP) or total/direct bilirubin > 1.5x ULN at screening or Day -
•Participants with confirmed Gilbert's syndrome will not be permitted to enroll in the study.
•11.History of chronic diarrhea, malabsorption, unexplained weight loss, food allergies or intolerance deemed clinically significant by the PI/medical delegate.
•12.History of cerebral hemorrhage (e.g., post-traffic accident), stroke, or cerebrovascular disease.
•13.Participants judged by the PI/medical delegate to have any condition or history that may alter or increase bleeding tendency.
•14.Participants regularly using drugs affecting coagulation function within 3 months before screening, or had received anticoagulant therapy such as heparin, low-molecular-weight heparin, fibrinolytic agents, etc. in the same timeframe.
•15.Participants with conditions that may, in the opinion of the PI/medical delegate, significantly affect normal venous blood collection.
•16.Positive results for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) antibody at screening.
•17.Donated or lost >500 ml of blood in the previous 3 months prior to screening, donation of bone marrow or peripheral stem cells within 90 days prior to Day 1, or donation of plasma within 30 days prior to Day
•18.Participants who have participated in any investigational drug study within the past 3 months or 5 half-lives (whichever is longer) prior to dosing, or have participated in any investigational device study within the past 3 months prior to dosing.
•19.Previous exposure to LWP
•20.Use of prescription medications, vaccination, or any drugs known to induce or inhibit CYP3A4/5 or P-glycoprotein within 30 days or 5 half-lives (whichever is longer) prior to the first dose of study drug.
•21.Use of over-the-counter (OTC) medication or supplements (including vitamins, dietary supplements, herbal medicines, homoeopathy, etc.) within 14 days or 5 half-lives (whichever is longer), prior to receiving the first dose of study drug that might have impact on the clinical trial as per the PI/medical delegate's discretion. Acetaminophen (paracetamol) is permitted if provided maximum daily dose does not exceed 2000 mg.
•22.Hospital admission or major surgery within 6 months prior to screening, or history of bariatric surgery.
•23.A history of prescription drug misuse (as assessed by the PI/medical delegate), or positive urine drug screen at screening or Day -
•24.Regular consumption of more than 10 standard alcoholic drinks per week or more than 4 standard alcoholic drinks on any one day, where 1 standard drink is 10 g of pure alcohol and is equivalent to 285 mL beer [4.9% Alc/Vol], 100 mL wine [12% Alc/Vol], or 30 mL spirit [40% Alc/Vol]).
•25.Consumes more than 2 cigarettes or equivalent nicotine-containing products per week, and/or is unwilling to abstain from the use of such products for 7 days prior to Day -1 through to EOS. Positive cotinine test at Day -
•26.Use of cannabis or cannabidiol (CBD) containing products, in any form (e.g., edibles, oil, lotion, smoking) within 30 days prior to study drug administration on Day 1, regardless of legality within a given State, County or Region.
•27.Participant is pregnant (as determined by pregnancy test result at screening or Day -1) or breastfeeding.
•28.Participants who had consumed any food or beverage containing caffeine, alcohol, xanthine, Seville orange, pomelo, dragon fruit, starfruit, guava or grapefruit within 48 hours before each admission to the CRU.
•29.A positive screen for alcohol at screening or Day -
•30.Employee or family member of the Investigator (PI/medical delegate), study site personnel, or sponsor.
•31.Food Effect study part only: unwilling to consume a high-fat meal consisting of eggs, bacon, butter, white bread and full cream milk.
•32.Unable or unwilling to comply with the study restrictions and requirements
•33.Participant developed an acute condition during the screening phase or before administration of the study drug; any other condition or finding that in the PI/medical delegate's opinion would put the participant or study conduct at risk if the participant were to be included in the study.

研究组 & 干预措施

Single Ascending Dose - 600 mg

Experimental

干预措施: LWP779 (Drug)

Single Ascending Dose - 600 mg

Experimental

干预措施: Placebo of LWP779 (Drug)

Single Ascending Dose - 150 mg

Experimental

干预措施: LWP779 (Drug)

Single Ascending Dose - 150 mg

Experimental

干预措施: Placebo of LWP779 (Drug)

Single Ascending Dose - 300 mg

Experimental

干预措施: LWP779 (Drug)

Single Ascending Dose - 300 mg

Experimental

干预措施: Placebo of LWP779 (Drug)

Single Ascending Dose - 900 mg

Experimental

干预措施: LWP779 (Drug)

Single Ascending Dose - 900 mg

Experimental

干预措施: Placebo of LWP779 (Drug)

Single Ascending Dose - 1200 mg

Experimental

干预措施: LWP779 (Drug)

Single Ascending Dose - 1200 mg

Experimental

干预措施: Placebo of LWP779 (Drug)